<DOC>
	<DOCNO>NCT02018510</DOCNO>
	<brief_summary>The propose study first-in-man phase I study aims evaluate safety , tolerability pharmacokinetics 3BNC117 HIV-infected HIV-uninfected subject , antiretroviral activity HIV-infected subject .</brief_summary>
	<brief_title>A Phase 1 , Open Label , Dose-escalation Study Safety , Pharmacokinetics Antiretroviral Activity 3BNC117</brief_title>
	<detailed_description>In preclinical study carry humanized mice non-human primate , 3BNC117 alone combination neutralize antibody lead protection HIV-1 SHIV infection also sustain suppression HIV-1 plasma viremia . The aim protocol evaluate safety , tolerability pharmacokinetics profile 3BNC117 HIV-infected HIV-uninfected subject , antiretroviral activity HIV-infected subject .</detailed_description>
	<criteria>Group 1 ( HIVuninfected ) : Adult male female , age 18 65 Amenable HIV risk reduction counsel agrees maintain behavior consistent low risk HIV exposure ; If sexually active male female , participate sexual activity could lead pregnancy , agree use effective method contraception throughout study . Groups 25 ( HIVinfected ) : Age 18 65 HIV infection confirm ELISA immunoblot Groups 2AD ART HIV1 plasma RNA level 100,000 copies/ml , ART least 8 week HIV1 plasma RNA level 2,000100,000 copies/ml standard assay 2 occasion least 1 week apart ; Group 2E Untreated HIVinfected ( ART least 8 week ) : HIV1 RNA plasma level 2,000 100,000 copies/ml ; Group 3 Untreated HIV controller ( ART least 8 week ) : HIV1 RNA plasma level &lt; 2,000 copies/ml standard assay , 2 occasion , least 1 week apart , ARTnaive . Group 4 ART treat HIV1 RNA plasma level &gt; 20 copies/ml standard assay 2 occasion , least 1 week apart , combination antiretroviral therapy ; Groups 5A 5B ART treat HIV1 RNA plasma level &lt; 20 copies/ml standard assay 2 occasion , least 1 week apart , combination antiretroviral therapy ; Current CD4 cell count &gt; 300 cells/µl If sexually active male female , participate sexual activity could lead pregnancy , agree use effective method contraception throughout study . Exclusion criterion : Group 1 ( HIVuninfected ) : Confirmed HIV1 HIV2 infection ; History immunodeficiency autoimmune disease ; use systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month ; Any clinically significant acute chronic medical condition opinion investigator would preclude participation ; Within 12 month prior enrollment , volunteer history sexually transmitted disease ; Hepatitis B ( surface antigen , HbsAg ) hepatitis C ( HCV antibody ) ; Laboratory abnormalities parameter list : Absolute neutrophil count ≤ 2,000 Hemoglobin ≤ 12 gm/dL female ; ≤ 13.5 gm/dL male Platelet count ≤ 140,000 ALT ≥ 1.25 x ULN AST ≥ 1.25 x ULN Total bilirubin ≥ 1.1 ULN Creatinine ≥ 1.1 x ULN Coagulation parameter ( PT , PTT , INR ) ≥ 1.1 x ULN Pregnancy breastfeed ; Any vaccination within 14 day prior 3BNC117 administration ; Receipt experimental HIV vaccine past monoclonal antibody therapy kind past ; Participation another clinical study investigational product currently within past 12 week , expect participation study . Groups 25 ( HIVinfected ) : History AIDSdefining illness History systemic corticosteroid , immunosuppressive anticancer , medication consider significant trial physician within last 6 month ; Any clinically significant acute chronic medical condition , HIV infection , opinion investigator would preclude participation ; Hepatitis B ( surface antigen , HbsAg ) hepatitis C ( HCV antibody ) ; Laboratory abnormalities parameter list : Absolute neutrophil count ≤ 1,300 Hemoglobin ≤ 10 gm/dL Platelet count ≤ 125,000 ALT ≥ 2.0 x ULN AST ≥ 2.0 x ULN Total bilirubin ≥ 1.1 ULN Creatinine ≥ 1.1 x ULN Coagulation parameter ≥ 1.1 x ULN ; Current antiretroviral regimen include either maraviroc enfuvirtide ; Pregnancy breastfeeding ; Any vaccination within 14 day prior 3BNC117 administration ; Receipt experimental HIV vaccine monoclonal antibody therapy kind past ; Participation another clinical study investigational product currently within past 12 week , expect participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>HIV</keyword>
</DOC>